Raymond James Sees Weakness in Priority Healthcare

Analyst John Ranson says the hepatitis C market is weakening further, as generic competition looms

Raymond James sees weakness in Priority Healthcare (PHCC ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.